Dietrich Ruess
Principal Investigator
Department of General and Visceral Surgery, Center for Surgery
Medical Center University of Freiburg
Hugstetter Straße 55
79106 Freiburg
- +49 761 270-24010
- dietrich.ruess@uniklinik-freiburg.de
- Homepage
Current position
Managing Senior Physician/Surgeon, PI in the Department of General and Visceral Surgery, Center for Surgery
Academic training
| 2021–2023 | MBA Health Care Management, Campus Akademie, Universität Bayreuth |
| 2005 - 2011 | Medical School, Eberhard-Karls-Universität Tübingen; Internships in Haifa (ISR), Paris (FRA), New York City (USA) |
Advanced academic qualifications
| 2012 | Doctorate (Dr. med.), Department of Immunology, Eberhard-Karls-Universität Tübingen |
Postgraduate positions
| 2025 | Board Certification: Intensivmedizin |
| Since 2024 | Managing Senior Physician/Surgeon |
| 2023 | Board certification: Spezielle Viszeralchirurgie |
| Since 2022 | Attending Surgeon |
| 2022 | Habilitation, Faculty of Medicine, University of Freiburg |
| 2021-2022 | Berta-Ottenstein Advanced Clinician Scientist Program Faculty of Medicine, University of Freiburg |
| Since 2021 | PI + Fellow Deutsches Konsortium für Translationale Krebsforschung |
| Since 2021 | PI CRC 1479 “OncoEscape” Deutsche Forschungsgemeinschaft |
| Since 2020 | Head of Pancreas + Sarcoma Surgery Subdivisions, Department of General and Visceral Surgery, MCUF Visceral organ retrieval and transplant surgeon, |
| Since 2020 | Max-Eder Junior Research Group Leader, Stiftung Deutsche Krebshilfe |
| 2020 | Board certification: Viszeralchirurgie |
| Since 2018 | Visceral organ retrieval and transplant surgeon, German Foundation for Organ Transplantation (DSO) |
| 2015–2018 | Resident Surgeon, Department of General and Visceral Surgery, MCUF |
| 2015 | Board certification: Notfallmedizin |
| 2011-2015 | Resident Surgeon, Department of General and Visceral Surgery, MCUF |
Miscellaneous (Honors, Awards)
| 2025 | Abstract prize (PhD cand. P. Hafner, M.Sc.), United European Gastroenterology |
| 2024 | Werner-Creutzfeldt Promotionsstipendium (PhD cand. S. Keller, M.Sc.), German Pancreatic Club |
| 2023 | Abstract prize (PhD cand. S. Keller, M.Sc.), German Pancreatic Club |
| 2023 | Theodor-Billroth Habilitationspreis, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV) |
| 2022 | Abstract prize (PhD cand. P. Hafner, M.Sc.), European Pancreatic Club |
| 2022 | YOUPPIE Young Investigator Award, European Pancreatic Club |
| 2021 | Competitive Full Stipend for the MBA Health Care Management program, University of Bayreuth, Campus Akademie |
| 2021 | Selected as a member of the Academy of Excellence (Exzellenzakademie), Congregation of the Heads of Academic Visceral Surgery in Germany |
| Since 2020 | Max-Eder Junior-PI Fellow, German Cancer Aid |
| 2018 | Württembergischer Krebspreis, Dres. Bayer Stiftung |
| 2018 | Travel grant, European Pancreatic Club (EPC) |
| 2017 | Abstract prize, United European Gastroenterology (UEG) |
| 2017 | Fellowship, Mildred-Scheel-Cancer-Conference, Deutsche Krebshilfe |
| 2016 | Abstract prize + oral free paper award, UEG |
| 2015 | Abstract prize, Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Hafner P, Keller SJ, Chen X, Alrawashdeh A, Jumaa H, Nollmann FI, Besson S, Kemming J, Gorka O, Das T, Appiah B, Lehmann A, Li M, Apostolova P, Bengsch B, Zeiser R, Tholen S, Schilling O, Groß O, Vlachos A, Wittel UA, von Elverfeldt D, Reichardt W, Boerries M, Andrieux G, Heynen GJ, Fichtner-Feigl S, Hannibal L, Ruess DA. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Signal Transduct Target Ther. 2026 Jan 16;11(1):33. doi: 10.1038/s41392-025-02563-7.
Bakırdöğen D, Görgülü K, Xin J, Richter L, Alcalá S, Ruiz-Cañas L, Dai C, Frank KJ, Wu N, Diakopoulos KN, Ozturk H, Demircioğlu D, Peschke K, Ranjan R, Fusco F, Martinez-Useros J, Fernandez-Aceñero MJ, Chhabra NF, López-Gil JC, Ai J, Ruess DA, Kaya-Aksoy E, Schmidt F, Kohlmann L, Berninger A, Yangin H, Schicktanz F, Steiger K, Demir IE, Schmid RM, Reichert M, Adli M, Lesina M, Sainz B Jr, Algül H. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Mol Cancer. 2025 Dec 15. doi: 10.1186/s12943-025-02486-5. Epub ahead of print.
Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. 2025 Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000. Epub ahead of print.
Reichardt W, Gewalt T, Hafner P, Keller SJ, Chen X, Alrawashdeh A, Li Y, Besson S, Fichtner-Feigl S, von Elverfeldt D, Jumaa H, Ruess DA. 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. J Magn Reson Imaging. 2025 Apr;61(4):1996-2008. doi: 10.1002/jmri.29589. Epub 2024 Aug 27.
Chen X, Keller SJ, Hafner P, Alrawashdeh AY, Avery TY, Norona J, Zhou J, Ruess DA. Tyrosine phosphatase PTPN11/SHP2 in solid tumors – bull’s eye for targeted therapy? Front Immunol. 2024 Mar 5;15:1340726. doi: 10.3389/fimmu.2024.1340726.
Elrakaybi A, Ruess DA, Lübbert M, Quante M, Becker H. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Cancers (Basel). 2022 Nov 30;14(23):5926. doi: 10.3390/cancers14235926.
Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Front Oncol. 2022 Jul 27;12:931774. doi: 10.3389/fonc.2022.931774.
Contact
